Perrigo Company plc Payments to Acquire Available-for-sale Securities
Perrigo Company plc (PRGO) reported Payments to Acquire Available-for-sale Securities of $0 for the 9-month period ending 2015-03-28, per its 10-Q filed 2015-04-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2015-04-29
- Perrigo Company plc payments to acquire available-for-sale securities for the quarter ending 2014-06-28 was $0.00.
- Perrigo Company plc payments to acquire available-for-sale securities for the quarter ending 2013-06-29 was $0.00.
- Perrigo Company plc payments to acquire available-for-sale securities for fiscal 2014 was $15.00M.
- Perrigo Company plc payments to acquire available-for-sale securities for fiscal 2013 was $0.00.
- Perrigo Company plc payments to acquire available-for-sale securities for fiscal 2012 was $0.00.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|
| 2015-03-28 | $0.00 10-Q · filed 2015-04-29 | ||
| 2014-06-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-14 | $15.00M 10-K · filed 2014-08-14 | |
| 2014-03-29 | $15.00M 10-Q · filed 2015-04-29 | ||
| 2013-06-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-14 | $0.00 10-K · filed 2014-08-14 | |
| 2013-03-30 | $0.00 10-Q · filed 2014-05-07 | ||
| 2012-06-30 | $0.00 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |